Enhancement of Doxorubicin by Encapsulation in Long Circulating Thermosensitive Liposomes Combined with Local Hyperthermia

  • Kazuo Maruyama
Part of the Biotechnology Intelligence Unit book series (BIOIU)


The therapeutic efficacy of antitumor drugs is restricted by dose-limiting toxicities to normal tissues in vivo, but would be greatly improved if the drugs could be selectively directed to the tumor sites and away from sensitive tissues. Liposomes have been proposed to be useful drug carriers for targeted drug delivery systems, and are under investigation in several therapeutic fields.1,2 In order to achieve maximum targeting, liposomes should remain in the systemic circulation for a long time. However, formulations of liposomes used in the past were rapidly removed from the circulation by the reticuloendothelial system (RES).3,4 It has been demonstrated recently that newly developed liposomes, containing either monosialoganglioside GM, (GM1)S or amphipathic polyethylene glycol (PEG),6–8 are not readily taken up by the macrophages in the RES and hence stay in the circulation for a relatively long period of time. More importantly, these long circulating liposomes, having small size (100–200 nm in mean diameter), showed significantly greater accumulation in solid tumors compared with the corresponding conventional liposomes. 9,10 These reports indicate that long circulating liposomes offer considerable potential for drug targeting to solid tumor.


Large Unilamellar Vesicle Local Hyperthermia Target Drug Delivery System Prolonged Circulation Prolonged Circulation Time 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Young RC, Ozols RE, Mayers CE. The anthracycline antineoplastic drugs. New Engl J Med 1981; 305: 139–153.PubMedCrossRefGoogle Scholar
  2. 2.
    Lasic D. Application of liposomes in pharmacology and medicine. In: Lasic D, ed. Liposomes from Physics to Applications. Amsterdam: Elsevier, 1993; 262–471.Google Scholar
  3. 3.
    Hwang KJ. Liposome pharmacokinetics. In: Ostro MJ, ed. Liposome from Biophysics to Therapeutics. New York: Marcel Dekker Inc. 1987: 109–156.Google Scholar
  4. 4.
    Senior JH. Fate and behavior in vivo: a review of controlling factors. Critical Review in Drug Carrier Systems 1987; 3123–139.Google Scholar
  5. 5.
    Allen TM, Chonn A. Large unilamellar liposomes with low uptake into the reticuloendotherial system. FEBS Lett 1987; 223: 42–46.PubMedCrossRefGoogle Scholar
  6. 6.
    Klibanov AL, Maruyama K, Huang L et al. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett 1990; 268:235-237.Google Scholar
  7. 7.
    Maruyama K, Yuda T, Okamoto A et al. Prolonged circulation time in vivo of large unilamellar liposomes composed of distearoyl phosphatidylcholine and cholesterol containing amphipathic poly(ethylene glycol). Biochim Biophys Acta 1992; 1128: 44–49.PubMedCrossRefGoogle Scholar
  8. 8.
    Allen TM, Hansen C, Martin FL et al. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta 1991; 1066: 29–36.PubMedCrossRefGoogle Scholar
  9. 9.
    Yuan F, Leuning M, Huang SK et al. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res 1994; 54: 3352–3356.PubMedGoogle Scholar
  10. 10.
    Unezaki S, Maruyama K, Hosoda J et al. Direct measurement of extravasation of polyethyleneglycol-coated liposomes into solid tumor tissue by in vivo fluorescence microscopy. Int J Pharm 1996; in press.Google Scholar
  11. u. Maruyama K, Unezaki S, Takahashi N et al. Enhanced delivery of doxorubicin to tumor by long circulating thermosensitive liposomes and local hyperthermia. Biochim Biophys Acta 1993; 1149: 209–216.Google Scholar
  12. 12.
    Maruyama K, Yuda T, Okamoto A et al. Effect of molecular weight in amphipathic polyethyleneglycol on prolonging the circulation time of large unilamellar liposomes. Chem Pharm Bull 1991; 39: 1620–1622.PubMedCrossRefGoogle Scholar
  13. 13.
    Olson F, Mayhew E, Maslow D et al. Characterization, toxicity, and therapeutic efficacy of adriamycin encapsulated in liposomes. Eur J Cancer Clin Oncol 1982; 18: 167–176.PubMedCrossRefGoogle Scholar
  14. 14.
    Herman EH, Rahman A, Ferrans VJ et al. Prevention of chronic doxorubicin cardiotoxicity in beagles by liposome encapsulation. Cancer Res 1983; 43: 54275432.Google Scholar
  15. 15.
    Hahn GM, Braun J, Har-Kedar I. Thermochemotherapy: Synergism between hyperthermia (42–43°C) and adriamycin (or Bleomycin) in mammalian cell inactivation. Proc Natl Acad Sci USA 1975; 72: 937–940.PubMedCrossRefGoogle Scholar
  16. 16.
    Mayer LD, Bally MB, Hope MJ et al. Uptake of antineoplastic agents into large unilamellar vesicles in response to membrane potential. Biochim Biophys Acta 1985; 816: 294–302.PubMedCrossRefGoogle Scholar
  17. 17.
    Wu MS, Robbins JC, Bugianesi RL et al. Modified in vivo behavior of liposomes containing synthetic glycolipids. Biochim Biophys Acta 1981; 674: 19–29.PubMedCrossRefGoogle Scholar
  18. 18.
    Corbett TH, Griswold D, Roberts BJ et al. Biology and therapeutic response of a mouse mammary adenocarcinoma (16/C) and its potential as a model for surgical adjuvant chemotherapy. Cancer Treat Rep 1978; 60: 1471–1488.Google Scholar
  19. 19.
    Unezaki S, Matsumura M, Ohtani Y et al. Preparation and evaluation of temperature-sensitive liposomes containing doxorubicin by pH gradient method. Drug Delivery System 1992; 7: 37–41.CrossRefGoogle Scholar
  20. 20.
    Iga K, Hamaguchi N, Igari Y et al. Heat-specific drug release of large unilamellar vesicle as hyperthermia-mediated targeting delivery. Int J Pharm 1989; 57t241–251.Google Scholar
  21. 21.
    Weinstein JN, Magin RL, Yatvin MB et al. Liposomes and local hyperthermia: Selective delivery of methotrexate to heated tumor. Science 1979; 204: 188–191.PubMedCrossRefGoogle Scholar
  22. 22.
    Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA 1988; 85: 6949–6953.PubMedCrossRefGoogle Scholar
  23. 23.
    Unezaki S, Maruyama K, Ishida O et al. Enhanced tumor targeting of doxorubicin by ganglioside GM1-bearing long circulating liposomes. J Drug Target 1993; iiz87–292.Google Scholar
  24. 24.
    Senior J, Delgardo C, Fisher D et al. Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly (ethylene glycol)-coated vesicles. Biochim Biophys Acta 1991; 1062: 77–82.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • Kazuo Maruyama

There are no affiliations available

Personalised recommendations